{"id":"zolpidem-myslee","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Drowsiness/somnolence"},{"rate":"5-10%","effect":"Headache"},{"rate":"1-5%","effect":"Amnesia"},{"rate":"1-2%","effect":"Complex sleep behaviors"},{"rate":"variable with chronic use","effect":"Dependence/tolerance"}]},"_chembl":{"chemblId":"CHEMBL3989820","moleculeType":"Small molecule","molecularWeight":"764.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zolpidem binds preferentially to the alpha-1 subunit of GABA-A receptors in the brain, potentiating the effect of the inhibitory neurotransmitter GABA. This increases chloride ion influx into neurons, hyperpolarizing the cell membrane and reducing neuronal excitability. The result is sedation and facilitation of sleep initiation with minimal muscle relaxation or anticonvulsant effects compared to non-selective benzodiazepines.","oneSentence":"Zolpidem is a selective benzodiazepine receptor agonist that enhances inhibitory GABA signaling in the central nervous system to promote sleep onset.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:37.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia (sleep onset and maintenance)"}]},"trialDetails":[{"nctId":"NCT00432198","phase":"PHASE4","title":"Zolpidem Postmarketing Study in Adolescent Patients With Insomnia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-02","conditions":"Insomnia","enrollment":122},{"nctId":"NCT00999219","phase":"PHASE3","title":"A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-03","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Myslee","FK199B"],"phase":"marketed","status":"active","brandName":"Zolpidem (Myslee®)","genericName":"Zolpidem (Myslee®)","companyName":"Astellas Pharma Inc","companyId":"astellas-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zolpidem is a selective benzodiazepine receptor agonist that enhances inhibitory GABA signaling in the central nervous system to promote sleep onset. Used for Insomnia (sleep onset and maintenance).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}